Search Results
May 26, 2026, 00:35 ET Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient,
More news about: Akeso, Inc.
May 23, 2026, 10:00 ET Meet Clicklinks: The Innovation Hub for Original Drug Discovery
scientific scrutiny. Not luck — data.Gateway 4: Innovative TechnologiesA gathering place for cutting-edge technology platforms: mRNA-encoded antibodies, AI-driven molecular generation, organoid evaluation systems, and more. The frontier explorer's arsenal is always open to you.Gateway
More news about: Sanyou Bio
May 20, 2026, 10:00 ET Sanyou Bio Launches SAI-DA 1.0, the AI-Drug Accelerator
volumesCore Technology AccelerationSimultaneous advancement of cutting-edge technologies including DAC, AOC, POC, mRNA-mAb, siRNA, and CAR-T/TCR cell therapiesDevelopment of automated, intelligent "lights-out factories" and BCT-CR drug screening systemsEstablishment
More news about: Sanyou Bio
May 20, 2026, 06:57 ET METiS TechBio to Present Late-Breaking Data on Near-Complete Cardiomyocyte Delivery at CRS 2026
under the NanoForge platform to identify LNPs with specific tissue tropism. The research team evaluated candidate LNPs in mTmG mouse models, using Cre-mRNA to induce eGFP expression as a readout for functional intracellular delivery. After identifying lead lipids with heart-specific tropism, the team further
More news about: METiS TechBio
May 19, 2026, 08:00 ET etherna's mRNA and LNP Platforms Propel Dropshot Therapeutics' Renal Target to the Clinical Stage
Belgium, May 19, 2026 /PRNewswire/ -- etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, today announces a major milestone in its ongoing partnership with Dropshot
More news about: etherna
May 17, 2026, 21:12 ET ACROBiosystems Innovation Day in Zürich bringt führende Köpfe zur Erkundung neuer Biotech-Grenzen zusammen
bei der Herstellung durch die Immobilisierung von Enzymen. In ihrem Vortrag „Immobilized Enzymes for Smart Biologics Manufacturing: Applications in mRNA and ADC Production" stellten sie eine patentierte Technologie vor, die die Stabilität und Wiederverwendbarkeit von Enzymen erhöht. Sie stellten zwei
More news about: ACROBiosystems Group
May 17, 2026, 21:10 ET Zurich accueille la journée de l'innovation d'ACROBiosystems : les plus grands esprits s'unissent pour explorer les frontières de la biotechnologie
de la fabrication par immobilisation des enzymes. Dans leur exposé intitulé « Immobilized Enzymes for Smart Biologics Manufacturing: Applications in mRNA and ADC Production » (Les enzymes immobilisés pour une fabrication intelligente des médicaments biologiques : applications dans la production d'ARNm
More news about: ACROBiosystems Group
May 15, 2026, 12:27 ET BioSpace Wins Several Accolades for Biopharma Journalism, Including 2026 Neal and Azbee National Gold Awards
and Best Commentary for their submissions "Rare Diseases, Cell and Gene Therapy Face Pivotal Moment" and "Weighing In on RFK Jr.'s Attack on Vaccines, mRNA Technology," respectively.The BioSpace team was awarded National Gold and Regional Gold for Industry News Coverage in the 2026 Azbee Awards
More news about: BioSpace
May 15, 2026, 10:25 ET Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
Advanced Glycation End-products (RAGE), a genetically validated driver of inflammation in chronic obstructive pulmonary disease (COPD). RB042 redirects pre-mRNA expression to the protective soluble esRAGE isoform over pro-inflammatory membrane-bound mRAGE, potentially shifting the isoform balance disrupted in
More news about: Atisama Therapeutics
May 15, 2026, 03:43 ET Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient,
More news about: Akeso, Inc.
May 14, 2026, 08:10 ET CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
the field is making that reset accessible to far more patients, without the complexity of ex vivo manufacturing or lymphodepletion. CREATE's in vivo mRNA-LNP approach to CAR-T directly addresses that, and I am excited to support the team as they advance CRT-402 to the clinic."CREATE's Scientific
More news about: CREATE Medicines, Inc.
May 14, 2026, 08:00 ET CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
the field — generating the translational foundation that informs development across both autoimmune disease and oncology. The company's proprietary mRNA-LNP platform programs immune cells directly inside the body, enabling a rapid, iterative product engine designed to compress concept-to-clinic timelines.
More news about: CREATE Medicines, Inc.
May 13, 2026, 22:09 ET METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals
product designed to efficiently activate anti-tumor immunity within specific organs in vivo, with the potential to become the world's first in vivo mRNA-encoded TCE therapy for solid tumors, for the treatment of liver cancer and other advanced solid tumors with liver metastases. Leveraging its AiLNP
More news about: METiS TechBio
May 13, 2026, 21:41 ET 晶泰生態賦能項目劑泰科技成功IPO，產業稀缺生態平台全面邁入價值兌現期
全球AI藥物遞送第一股:突破「送藥」瓶頸的稀缺技術平台劑泰科技此次上市吸引市場高度關注，核心在於其直面核酸與基因治療時代最棘手的工程難題之一——如何將藥物精准送達病灶。傳統脂質納米顆粒（LNP）遞送存在根本性局限：絕大多數 LNP 被肝髒被動捕獲，肝外遞送效率極低，嚴重制約 mRNA、基因編輯等新一代療法的臨床應用。劑泰自研的全球首個 AI 納米遞送平台 NanoForge，正是在這一瓶頸上實現系統級突破，有望像精准制導的火箭，解決新分子成藥的「最後一公裡」問題，將傳統遞送方法無法勝任的分子與靶點納入射程，打破潛力分子因遞送問題而臨床折戟的成藥魔咒。基於 NanoForge
More news about: 晶泰科技
May 13, 2026, 08:04 ET ERS Genomics and Aurigene Sign CRISPR/Cas9 License Agreement to Advance Precision Genome Editing in Drug Discovery
commercial-scale supply.The expertise spans across modalities like monoclonal antibodies, bi-specifics, multi-specifics, Antibody Drug Conjugates, mRNA, immuno-fusion proteins and recombinant proteins.For more information, please visit
More news about: ERS Genomics
May 13, 2026, 06:00 ET Phylex BioSciences demonstrates power of AI-derived mRNA nanoparticle vaccine technology by designing ready-to-manufacture Andes hantavirus vaccine in two days
research project to develop an AI-derived mRNA nanoparticle vaccine against the Andes hantavirus, recently responsible for the infection outbreak in the cruise ship MV Hondius and the evacuation of its passengers in twelve different countries. The Phylex mRNA nanoparticle vaccine technology was already
More news about: Phylex BioSciences
May 12, 2026, 11:00 ET Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
business analytics consulting capabilities with Porton Advanced's end-to-end GMP manufacturing infrastructure, spanning lentiviral vectors, AAV, mRNA/LNP, plasmids, and engineered cell therapies including CAR-T, CAR-NK, and iPSC-derived products. Together, the two organizations will offer client companies
More news about: Porton Advanced
May 12, 2026, 03:04 ET ACROBiosystems Innovation Day Lands in Zurich: Top Minds Unite to Explore Biotech Frontiers
addressed manufacturing challenges through enzyme immobilization. In their talk "Immobilized Enzymes for Smart Biologics Manufacturing: Applications in mRNA and ADC Production", they presented a patented technology that enhances enzyme stability and reusability. They presented two case studies: immobilizing
More news about: ACROBiosystems Group
May 11, 2026, 07:51 ET ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness
and manufacturing of next‑generation therapies. With deep expertise in cell and gene therapy, ProBio delivers integrated, end‑to‑end solutions across mRNA, plasmid DNA, viral vectors, and in vivo CAR‑T therapies.ProBio's scalable, GMP‑compliant platforms support partners from early development through
More news about: ProBio Inc.
May 07, 2026, 07:05 ET REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
level)Date/Time: Thursday, May 14, 5:00 – 6:30pm ETTitle: Single-nuclei transcriptomic analysis of skeletal muscle mRNA in mdx mice treated with RGX-202, an AAV vector encoding micro-dystrophinPoster: 3499Presenter: Justin Glenn, Ph.D.,
More news about: REGENXBIO Inc.
May 06, 2026, 23:29 ET Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance Global Scientific Strategy and Innovation
antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.By integrating Harbour Mice®, single-B cell screening technology, NonaCarFxTM (a direct CAR-function-based
More news about: Nona Biosciences
May 06, 2026, 17:11 ET /C O R R E C T I O N -- Mana.bio/
member of its board of directors, Michelle Lynn Hall as a board observer, and Guy Van Meter as strategic advisor. These additions bring deep expertise in mRNA therapeutics, LNP delivery, business development, and strategic partnerships to support the company's next phase of growth.Thaminda Ramanayake
More news about: Mana.bio
May 06, 2026, 09:00 ET Diakonos Oncology Awarded Fast Track Designation by FDA for DOC1021 (dubodencel) in Unresectable or Metastatic Cutaneous Melanoma
patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens.The unique double-loading approach,
More news about: Diakonos Oncology
May 05, 2026, 21:30 ET Nona Biosciences Evolves Brand to Reflect Next Phase of Growth in Biotherapeutic Innovation
antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.By integrating Harbour Mice®, single-B cell screening technology, NonaCarFxTM (a direct CAR-function-based
More news about: Nona Biosciences
May 05, 2026, 08:20 ET Mel-Mont Medical Recognized at ASCCP with the Best Innovative Technology in HPV mRNA-Based Cervical Cancer Triage
Pathology (ASCCP) Scientific Meeting with the Best Innovative Technology Award. The award-winning study highlighted Mel-Mont Medical's Proofer 7 HPV mRNA E6/E7 Biomarker Test, available through the company's
More news about: Mel-Mont Medical